Atlas market file · Equity · United States
DENTSPLY SIRONA Inc.XRAY
- Last close
- 12.12
- Change
- -7.97%
- 96-bar range
- 9.41 – 14.44
- As of
- 7 Aug 2026
DENTSPLY SIRONA Inc. is a dental equipment & supplies issuer listed as XRAY on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-52.11% over the window).
Source rail: Yahoo Finance chart API (XRAY). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for XRAY. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
XRAY public profile
Dental equipment & supplies issuer. DENTSPLY SIRONA Inc. is connected to current market context, cited company sources and its retained research file.
DENTSPLY SIRONA Inc. trades as XRAY on NASDAQ. DENTSPLY SIRONA Inc. (XRAY) has a latest verified close of 12.12, down 7.97%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files XRAY under USA Stocks for browsing.
What changed for DENTSPLY SIRONA Inc. today
Dentsply Sirona Inc. filed its latest 10-Q on 5 May 2026, and the numbers read like a dental patient’s worst nightmare: revenue of $880m at 31 March 2026 was paired with a net loss of $10m, while operating income cratered to minus $35m. Diluted earnings per share clocked in at minus five cents on 199.9m shares, a sum that would make any CFO wince before breakfast. Cash and equivalents stood at $190m, barely enough to cover next quarter’s payroll if the invoices from the cloud-services provider arrived early. (source: XRAY SEC EDGAR 10-Q, 2026-05-05, https://www.sec.gov/Archives/edgar/data/818479/000081847926000149/xray-20260331.htm)
The company markets itself as a one-stop shop for digital dentistry: Primescan intraoral scanners with a 60-minute battery buffer, Sinius and Intego chairs that glide on Windows 11, and LEDView Plus lights that promise shadow-free cavities. The product pages look sleek, the press releases hum with innovation, and the SEC filings quietly confess a $63m cloud-services commitment stretching to 2028-an obligation that smells less like a growth platform and more like an IT mortgage hanging around a company already short on operating cash. (source: Intraoral Dental Scanners | Dentsply Sirona, https://www.dentsplysirona.com/en-gb/explore/digital-dentistry/product-topics/intraoral-scanning-and-digital-impression.html; XRAY SEC EDGAR 10-Q, 2026-05-05, https://www.sec.gov/Archives/edgar/data/818479/000081847926000149/xray-20260331.htm)
Filings show assets of $5.23bn versus liabilities of $3.91bn, leaving shareholders staring at $1.32bn of equity that is notionally solid but operationally thin. Research and development spending hit $44m, inventory climbed by $23m to $659m, and net cash from operations was a modest $40m-hardly the dynamo you’d expect from a global dental-equipment franchise still hawking chairs and scanners as if 2021 never ended. (source: XRAY SEC EDGAR 10-Q, 2026-05-05, https://www.sec.gov/Archives/edgar/data/818479/000081847926000149/xray-20260331.htm)
The company’s 13G filing on 8 July 2026 reveals one unnamed beneficial owner holding 6.5% of the equity, a neat snapshot of how concentrated ownership can persist even as the income statement wilts. Form 4 and Form 3 drip-feeds through late June and July show routine director share transactions, but none that meaningfully alter the optics of a board overseeing a company whose market narrative still outruns its margin reality. (source: XRAY SCHEDULE 13G/A, 2026-07-08, https://www.sec.gov/Archives/edgar/data/818479/000201238326001935/xslSCHEDULE_13G_X02/primary_doc.xml; XRAY 3, 2026-07-21, https://www.sec.gov/Archives/edgar/data/818479/000081847926000235/xslF345X06/form3.xml)
The balance sheet’s inventory build of $23m looks less like a supply-chain win and more like a sales-force cry for help. With $190m in cash and $3.91bn in liabilities, the company’s liquidity cushion is narrower than the margin on a single molar. The SEC’s company facts JSON and submissions JSON confirm the datapoints above but add no new earnings surprises; the file remains a glass-half-empty story of a franchise still selling smiles while its income statement yawns. (source: XRAY SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0000818479.json; XRAY SEC submissions JSON, https://data.sec.gov/submissions/CIK0000818479.json)
If you want the company’s own gloss on its products, the official pages for Primescan, Sinius, Intego, and LEDView Plus are polished enough to brighten any waiting room, but the filings remind you that polish does not pay dividends. The tension is simple: the products are real, the customers exist, and the cash still has to turn up at the end of the quarter. (source: Intraoral Dental Scanners | Dentsply Sirona, https://www.dentsplysirona.com/en-gb/explore/digital-dentistry/product-topics/intraoral-scanning-and-digital-impression.html; Intego Dental Chair | Dentsply Sirona, https://www.dentsplysirona.com/en-gb/explore/dental-chairs/brands/other-products/intego.html; Sinius Dental Chair | Dentsply Sirona, https://www.dentsplysirona.com/en-gb/explore/dental-chairs/brands/other-products/sinius.html; Dental Lights | Overhead LED Operatory Lights | Dentsply Sirona, https://www.dentsplysirona.com/en-gb/explore/dental-chairs/brands/other-products/led-view-plus.html)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
XRAY technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on XRAY
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep XRAY research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
XRAY FAQ
What is DENTSPLY SIRONA Inc. (XRAY)?DENTSPLY SIRONA Inc. (XRAY) has a latest verified close of 12.12, down 7.97%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed...
DENTSPLY SIRONA Inc. (XRAY) has a latest verified close of 12.12, down 7.97%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for XRAY?DENTSPLY SIRONA Inc. (XRAY) has a latest verified close of 12.12, down 7.97%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...
DENTSPLY SIRONA Inc. (XRAY) has a latest verified close of 12.12, down 7.97%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files XRAY under USA Stocks for browsing.
How often is the XRAY page updated?The XRAY public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The XRAY public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for XRAY?The XRAY file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:XRAY. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The XRAY file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:XRAY. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on XRAY?Yes. The workstation can open XRAY, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open XRAY, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this XRAY page investment advice?No. The XRAY page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The XRAY page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →
XRAY
Equity · evidence first